Ophthalmic and Systemic Factors of Acute Nonarteritic Anterior Ischemic Optic Neuropathy in the Quark207 Treatment Trial
Mark J Kupersmith,Clare L Fraser,Rachelle Morgenstern,Neil R Miller,Leonard A Levin,Nathalie Jette,Quark207 NAION Study Group,Fraser Clare,Chen Celia,Shuey Neil,Colley Stephen,Ningli Wang,Hongliang Dou,Yong Zhong,Luosheng Tang,Quanhong Han,Sandner Dirk,Gamulescu Maria-Andreea,Eter Nicole,Wilhelm Helmut,Lorenz Katrin,Krishna G Santhosh,Kekunnaya Ramesh,Ambika S,Sharma Kumudini,Vivekanand Uttamrao Warkad,Saxena Rohit,Kumar S Mahesh,Das Dipankar,Hegade Atul,Mazumdar Shahana,Daighavane Sachin,Sachdeva Virender,Kalish Hadas,Klein Ainat,Huna-Baron Ruth,Leiba Hana,Goldenberg-Cohen Nitza,Shneck Marina,Kruger Joshua,Ciardella Antonio Pasquale,Virgili Gianni,Carta Arturo,Bianchi Marzoli Stefania,Sharon Tow,Chin Chee Fang,MacIntosh Peter,Bennett Jeffrey,Lam Byron,Katz Bradley,Williams Zoe,Lee Michael,Tamhankar Madhura,Banik Rudrani,Rauser Michael,Levy Marc,Liao Yaping Joyce,Luu James,Tibbetts Michael,Scales David,Lesser Robert,Patel Anil,Givre Syndee,Van Stavern Gregory,Hamilton Steven,Rismondo Vivian,Francis Courtney,Cestari Dean,Dinkin Marc,Pula John,Sudhakar Padmaja,Newman Steven,Tang Rosa,Chacko Joseph,Kedar Sachin,Quiros Peter,Frohman Larry,Volpe Nicholas,Sibony Patrick,Chen John,Mejico Luis,Kosmorsky Gregory,Alfaro Daniel Virgil,Katz David,Lee Andrew,DeLott Lindsey,Patel Vivek,Bose Swaraj,Peeler Crandall,Tariq Bhatti
DOI: https://doi.org/10.1016/j.ophtha.2024.01.011
IF: 14.277
Ophthalmology
Abstract:Purpose: We describe the baseline ophthalmic and cardiovascular risk factors across countries, race, and sex for the Quark207 treatment trial for acute nonarteritic anterior ischemic optic neuropathy (NAION). Design: Prospective, randomized controlled clinical trial. Participants: Adults 50 to 80 years of age with acute NAION recruited from 80 sites across 8 countries. Main outcome measures: Ophthalmic features of NAION and cardiovascular risk factors. Methods: We evaluated demographics and clinical and ophthalmologic data, including best-corrected visual acuity (BCVA) and average visual field total deviation (TD), in affected eyes and cup-to-disc ratio in fellow eyes at enrollment. We report the prevalence (mean and standard devition, and median and interquartile range [IQR]) of ophthalmic features and cardiovascular risk factors, stratified by country, race, and sex. We corrected for multiple comparisons using Dunn's test with Bonferroni correction for continuous variables and chi-square testing with Holm-Bonferroni correction for categorical variables. Results: The study enrolled 500 men and 229 women with a median age of 60 and 61 years (P = 0.027), respectively. Participants were predominantly White (n = 570) and Asian (n = 149). The study eye BCVA was 71 characters (IQR, 53-84 characters; approximately 0.4 logarithm of the minimum angle of resolution), and the TD was -16.5 dB (IQR, -22.2 to -12.6 dB) for stimulus III and -15.7 dB (IQR, -20.8 to -10.9 dB) for stimulus V. The vertical and horizontal cup-to-disc ratio was 0.1 (IQR, 0.1-0.3) for unaffected fellow eyes. The prevalence of cardiovascular risk factors varied among countries. The most notable differences were in the baseline comorbidities and ophthalmologic features, which differed between Asian and White races. Men and women differed with respect to a few clinically meaningful features. Conclusions: The cardiovascular risk factors in the NAION cohort varied among the 7 countries, race, and sex, but were not typically more prevalent than in the general population. Ophthalmic features, typical of NAION, generally were consistent across countries, race, and sex, except for worse BCVA and TD in China. Men have a frequency of NAION twice that of women. Having a small cup-to-disc ratio in the fellow eye was the most prevalent risk factor across all demographics. This study suggests that factors, not yet identified, may contribute to the development of NAION. Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.